Extended Data Fig. 7. Representative case (patient no. 3) showing target lesion shrinkage and subsequent progression adjacent to but away from G47∆ injected sites.

a Characteristic MRI changes are observed, resulting in a large clearing area within, and an enlargement of, the target lesion. b The target lesion is reduced in size at 6 months after the last G47Δ administration. At 12 months, while the target lesion keeps shrinking, a progression is seen in the brain adjacent to the target lesion anterior-medially. The progression continues at 24 months. The disease course since the initiation of G47Δ therapy was 31.4 months.